SABR for Renal Tumors
Recruiting
N/A
Interventional Study
Renal Tumor
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 90 (estimated)
- Sponsor
- University Health Network, Toronto · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm
* Histological or radiological diagnosis of renal tumor
* Inoperable: High risk for surgery or declined surgery
* ECOG performance status of 0-3
Exclusion Criteria:
* ≥5 active metastases
* Systemic therapy …
Contacts